19:45 IST
BSE
Annual Report
Speciality Medicines Annual Report
Speciality Medicines Limited has submitted its Annual Report for the financial year 2025-26 to the exchange, complying with regulatory filing requirements.
Speciality Medicines Ltd
- Share price
- ₹185.00
- Market cap
- ₹162.5 Cr
- Revenue (annual)
- ₹75.29 Cr
- Net profit (annual)
- ₹13.03 Cr
- P/E (TTM)
- 12.5×Sector 47.4×
- Promoter holding
- 43.43%
- FII holding
- 0.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Regulatory Approval 1Other Announcement 1Business Update 1Annual Report 1Annual General Meeting 1
Time
5 announcements with these filters
15:50 IST
BSE
Annual General Meeting
Speciality Medicines Annual General Meeting
Speciality Medicines Limited scheduled its 5th Annual General Meeting for September 28, 2026. The board also approved the draft Directors' Report for FY 2025-26.
17:07 IST
BSE
Regulatory Approval
Speciality Medicines Regulatory Approval
Speciality Medicines Limited received regulatory approval in Ethiopia for two additional pharmaceutical formulations, Olanzapine and Diazepam tablets. The company now has 12 registered products in Ethiopia.
17:03 IST
BSE
Business Update
Speciality Medicines Business Update
Speciality Medicines Limited received regulatory approval for two new products, Olanzapine and Diazepam tablets, in the Ethiopian market, strengthening its international export portfolio.
18:28 IST
BSE
Other Announcement
Speciality Medicines Other Announcement
Speciality Medicines Limited has appointed Capital Bridge Advisory Service Private Limited as its Investor and Public Relations agency to enhance its investor relations and communication efforts.